Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer

2.1 Pralsetinib (Gavreto, Roche) is indicated for 'the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor'.

2.2 The dosage schedule is available in the summary of product characteristics for pralsetinib.

2.3 The list price for 120 capsules of pralsetinib (100 mg) is £7,044 (excluding VAT, company submission).

2.4 The company has a commercial arrangement, which would have applied if the technology had been recommended.